You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Test volumes, revenues per test and costs per test improved during the quarter, the company said.
Clinical services revenues rose 56 percent to $92.6 million while pharma services grew 26 percent to $12.1 million.
Several groups are comparing Bionano with standard cytogenetic assays like karyotyping, FISH, or array CGH for blood cancer or genetic disease testing.
Test volumes, revenues per test and costs per test improved during the quarter, company executives said.
A brief recap of Genetics/Genomics news the week of Dec 14, 2018: AstraZeneca, NeoGenomics, Fluidigm, Luminex, Petco Foundation, and SQI Diagnostics
NeoGenomics will pay $125 million in cash and distribute 1 million shares of its stock to Genoptix, a clinical oncology lab, as part of the deal.
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.
Upon completion of the transaction, Rosetta will become a privately held subsidiary of Genoptix and its shares will cease to trade on the Nasdaq.
The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.
The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.
Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.
In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.